About Ozone Pharmaceuticals Limited
Data last updated:
Ozone Pharmaceuticals Limited is a public limited company based in New Delhi, Delhi, India, a subsidiary of 4Thd Pharma Private Limited. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 13 March 1991 and has been in existence for over 35 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U99999DL1991PLC043461. Its GSTIN is 07AAACO0056H1ZS (Delhi). The company holds 30 GST registrations, of which 22 are active.
The company has an authorised share capital of ₹7.5 Cr and a paid-up capital of ₹5.36 Cr. It was formerly known as Ozone Export India Private Limited and Ozone Pharmaceuticals Private Limited. It is led by directors including Subhash Chander Sehgal (Managing Director) and Anupam Verma (Whole-Time Director).
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 1 Lsc Block A – 3 Janakpuri, New Delhi, Delhi, India – 110058.
As per the financials filed for FY 2025, the company reported a revenue of ₹337.45 Cr, a decline of 1% compared to the previous year. For the same year it recorded a net loss of ₹8.79 Cr (net margin -2.6%) and EBITDA of ₹17.19 Cr (EBITDA margin 5.1%). Revenue has grown at a compounded annual rate (CAGR) of 8% over three years and 12% over five years.
The company has about 2,164 employees on its provident fund (EPFO) records.
The company is associated with 2 brands: Ozone Pharmaceutical and Ozone Signature. As per MCA filings, the company has open charges of ₹94.71 Cr and satisfied charges of ₹59.22 Cr on record. Court records list 132 cases involving the company, including 104 filed by the company and 28 filed against it; 34 cases are pending. The company has 28 deals on record (20 secondary share transfers, 8 funding rounds), with disclosed funding of ₹124.07 Cr; the latest was in March 2025. Its 9 peer companies in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 4 smaller; the largest is Bharat Parenterals Limited with revenue of ₹352 Cr. The company has 4 MSME Form 1 returns on record between 2018 and 2019, listing 401 overdue payments to 25 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website ozonepharma.com.
Company details
Name history
Ozone Pharmaceuticals has undergone 2 name changes throughout its history. The company was previously known as Ozone Export India Private Limited, and Ozone Pharmaceuticals Private Limited. The current legal name is Ozone Pharmaceuticals Limited.
| Company Name | Status |
|---|---|
| Ozone Pharmaceuticals Limited | Current |
| Ozone Export India Private Limited | Previous |
| Ozone Pharmaceuticals Private Limited | Previous |
CIN history
Ozone Pharmaceuticals has one previous CIN (Corporate Identification Number): U99999DL1991PTC043461. The current CIN is U99999DL1991PLC043461, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U99999DL1991PLC043461 | Current |
| U99999DL1991PTC043461 | Previous |
Contact details
Ozone Pharmaceuticals Limited's registered office is in New Delhi, Delhi. Its website is ozonepharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address1 Lsc Block A – 3 Janakpuri, New Delhi, Delhi, India – 110058
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Ozone Pharmaceuticals Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Ozone Pharmaceuticals operates two associated brands: Ozone Pharmaceutical and Ozone Signature. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| A diversified range of generic medicines is manufactured. | ozonepharma.com | |
| Multi-category organic beauty care products are offered online. | ozonesignature.com |
Business activity
The main business activity of Ozone Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Ozone Pharmaceuticals Limited, buy the company report.
Financials of Ozone Pharmaceuticals Limited
FY 2025 filings availableOzone Pharmaceuticals Limited reported revenue of ₹337.45 Cr (down 1% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue fell 1% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 12%. EBITDA fell 45% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹17.19 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹8.79 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 5.1% | ||||
| Net Profit Margin | -2.6% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Ozone Pharmaceuticals Limited, buy the company report.
Board of directors of Ozone Pharmaceuticals Limited
Ozone Pharmaceuticals has 8 current directors and 16 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Geeta Sehgal Also directs: 4Thd Pharma Private Limited, Ozonewest Private Limited | Director | 30 Dec 2009 | 16 Years 10 Months | Current |
| Anju Bala | Director | 21 Sep 2022 | 4 Years 1 Months | Current |
| Akarsh Kashyap | Director | 19 Oct 2015 | 11 Years 0 Months | Current |
| Dipak Kumar Singh Also directs: North East Mega Food Park Limited, Assam Agrotech Private Limited | Director | 01 Feb 2016 | 10 Years 9 Months | Current |
| Anupam Verma | Whole-Time Director | 01 Feb 2021 | 5 Years 9 Months | Current |
| Subhash Chander Sehgal Also directs: North East Mega Food Park Limited, Blip Initiatives LLP, Assam Agrotech Private Limited and 4 more | Managing Director | 21 Jun 1996 | 30 Years 4 Months | Current |
Peer comparison
Ozone Pharmaceuticals Limited is compared with the 9 companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Bharat Parenterals Limited | ₹352 Cr (FY 2025) | 32.0% | Vadodara, Gujarat, India | |||
| Geno Pharmaceuticals Private Limited | ₹349.47 Cr (FY 2025) | 14.0% | Goa, India | |||
| Sparsh Bio-Tech Private Limited | ₹346.49 Cr (FY 2025) | -29.0% | Jamnagar, Gujarat, India | |||
| Capsugel Healthcare Private Limited | ₹340.69 Cr (FY 2025) | 9.0% | Gurugram, Haryana, India | |||
| Walter Bushnell Enterprises Private Limited | ₹340.47 Cr (FY 2025) | 132.0% | Mumbai, Maharashtra, India | |||
| Ozone Pharmaceuticals Limitedthis company | ₹337.45 Cr (FY 2025) | -₹8.79 Cr | -2.6% | -1.0% | 2,164 | New Delhi, Delhi, India |
| G.D. Pharmaceuticals Private Limited | ₹334.15 Cr (FY 2025) | 26.0% | Kolkata, West Bengal, India | |||
| Titan Laboratories Private Limited | ₹332.25 Cr (FY 2025) | 22.0% | Mumbai, Maharashtra, India | |||
| Sainor Laboratories Private Limited | ₹328.35 Cr (FY 2025) | -34.0% | Hyderabad, Telangana, India | |||
| Softgel Healthcare Private Limited | ₹327.36 Cr (FY 2025) | 42.0% | Puduppakkam, Tamil Nadu, India |
To see the full peer comparison of Ozone Pharmaceuticals Limited, buy the company report.
Auditor
Ozone Pharmaceuticals Limited is audited by MSKA & Associates for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| MSKA & Associates | FY 2023 | 105047W |
Shareholding
The shareholding of Ozone Pharmaceuticals Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Ozone Pharmaceuticals Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 22 Nov 2024 | 101007173 | Others | ₹6.85 Cr | Open | |
| 14 Jun 2024 | 100967361 | Hdfc Bank Limited | ₹30.98 Lakh | Open | |
| 08 Feb 2024 | 100893040 | Hdfc Bank Limited | ₹1.29 Cr | Open | |
| 29 Nov 2023 | 100829966 | Axis Bank Limited | ₹76.47 Lakh | Open | |
| 04 Sep 2023 | 100837879 | Yes Bank Limited | ₹25 Cr | Open |
To see the full charge records of Ozone Pharmaceuticals Limited, buy the company report.
Total charge records: 26 View all charges
Deals & funding
Ozone Pharmaceuticals Limited has 28 deals on record (20 secondary share transfers, 8 funding rounds), with disclosed funding of ₹124.07 Cr; the latest was in March 2025.
Deals on record (5 of 28)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2025 | Secondary share transfer | Undisclosed | Seller: an individual |
| Feb 2025 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Mar 2024 | Secondary share transfer | Undisclosed | Buyer: 4Thd Pharma Private Limited Seller: Sagun Pharmaceuticals Private Ltd , Seagull Drugs Private Limited |
| Mar 2024 | Secondary share transfer | Undisclosed | Seller: an individual |
| Mar 2014 | Funding round | ₹1.63 Cr | Investors: Seagull Drugs Private Limited , Sagun Pharmaceuticals Private Ltd , an individual |
To see the full deal history of Ozone Pharmaceuticals Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Ozone Pharmaceuticals Limited has 132 court cases on record: 104 filed by Ozone Pharmaceuticals, 28 filed against it. 34 cases are pending and 98 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 71 | 15 | 28 |
| High courts | 56 | 10 | 6 |
| Supreme Court | 5 | 3 | 0 |
Cases on record (5 of 132)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, South West, Delhi | Cheque dishonour complaint | Filed by the company against Ms Oz Luxe Beauty and Wellness LLP and Ors | Pending |
| District court, South West, Delhi | Cheque dishonour complaint | Filed by the company against Smartcity Distributors LLP | Pending |
| District court, South West, Delhi | Cheque dishonour complaint | Filed by the company against G D H Pharma Pvt Ltd and 1 other | Pending |
| District court, South West, Delhi | Commercial suit | Filed by the company against Aashirwad Medicos Private Limited | Pending |
| District court, Ambala, Haryana | Civil suit | Filed against the company by M/S Navdeep Engineering Pvt Ltd. | Pending |
To see the full case history of Ozone Pharmaceuticals Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Ozone Pharmaceuticals Limited has 4 MSME Form 1 returns on record between 2018 and 2019, listing 401 overdue payments to 25 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 25)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Vapi Care Pharma Pvt Ltd | |||
| Shree Naina Containers Inc | |||
| Aditya Overseas | |||
| Shree Caps & Closures | |||
| Titanium Technologies (India) Private Limited |
To see the full MSME payment records of Ozone Pharmaceuticals Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Ozone Pharmaceuticals has 1 associated company. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.
Employees & EPFO
Ozone Pharmaceuticals Limited has a workforce of 2,164 employees on its EPFO records as of Mar 20, 2025, across 5 active EPFO establishments.
GST
Ozone Pharmaceuticals has 30 GST registrations: 22 active and 8 cancelled or inactive. The first 4 active GSTINs are listed below.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07AAACO0056H1ZS | Delhi | Active | 01 Jul 2017 |
| 02AAACO0056H1Z2 | Himachal Pradesh | Active | 01 Jul 2017 |
| 03AAACO0056H1Z0 | Punjab | Active | 01 Jul 2017 |
| 05AAACO0056H1ZW | Uttarakhand | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Ozone Pharmaceuticals Limited, buy the company report.
Recent activity
Ozone Pharmaceuticals Limited has 22 board changes on record since 1996: 8 appointments and 14 cessations. The latest: Surender Pal Mahi was appointed as Additional Director on 26 May 2025.
62 earlier events are in the company report.
Frequently asked questions
Ozone Pharmaceuticals is an active public limited company based in New Delhi, Delhi, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 13 March 1991 (35+ years old) and is registered under CIN U99999DL1991PLC043461.
Ozone Pharmaceuticals has 8 current directors:
- Subhash Chander Sehgal - Managing Director
- Anupam Verma - Whole-Time Director
- Geeta Sehgal - Director
- Anju Bala - Director
- Akarsh Kashyap - Director
- Dipak Kumar Singh - Director
- Neelam Oberoi - Director
- Surender Pal Mahi - Additional Director
The latest financial statements of Ozone Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Ozone Pharmaceuticals is 07AAACO0056H1ZS, registered in Delhi. The company has 30 GST registrations in all, of which 22 are active and 8 are cancelled or inactive. Other active GSTINs include 02AAACO0056H1Z2 (Himachal Pradesh), 03AAACO0056H1Z0 (Punjab), 05AAACO0056H1ZW (Uttarakhand).
The CIN (Corporate Identification Number) of Ozone Pharmaceuticals is U99999DL1991PLC043461. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Ozone Pharmaceuticals has 132 court cases on record: 104 filed by the company and 28 filed against it. 34 are pending. Most are in the district courts.
Ozone Pharmaceuticals was incorporated on 13 March 1991, making it 35+ years old. It is registered with the Registrar of Companies, Delhi.
Ozone Pharmaceuticals has 28 deals on record (20 secondary share transfers, 8 funding rounds), with disclosed funding of ₹124.07 Cr; the latest was in March 2025.
The peers of Ozone Pharmaceuticals by revenue are Bharat Parenterals Limited, Geno Pharmaceuticals Private Limited, Sparsh Bio-Tech Private Limited, Capsugel Healthcare Private Limited, Walter Bushnell Enterprises Private Limited and 4 more, all in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Surender Pal Mahi was appointed as Additional Director on 26 May 2025. Sanchi Sehgal ceased to be Director on 03 Mar 2024. Suraj Bhan Gupta ceased to be Director on 11 Apr 2023. Ozone Pharmaceuticals has 22 board changes on record in total.
Ozone Pharmaceuticals has 4 MSME Form 1 returns on record between 2018 and 2019, listing 401 overdue payments to 25 micro and small suppliers. The latest return was filed on 16 Jul 2019.
Ozone Pharmaceuticals can be reached through the website ozonepharma.com. Its registered office is in New Delhi, Delhi, India.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
